These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35308248)

  • 1. Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.
    Ye H; He Y; Zheng C; Wang F; Yang M; Lin J; Xu R; Zhang D
    Front Pharmacol; 2022; 13():816588. PubMed ID: 35308248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 4. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials.
    Koliaki C; Katsilambros N
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31878281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].
    Kobalava ZD; Yeshniyazov NV; Medovchshikov VV; Khasanova ER
    Kardiologiia; 2019 Apr; 59(4):76-87. PubMed ID: 31002044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation.
    Polovina M; Lund LH; Đikić D; Petrović-Đorđević I; Krljanac G; Milinković I; Veljić I; Piepoli MF; Rosano GMC; Ristić AD; Ašanin M; Seferović PM
    Eur J Heart Fail; 2020 Jan; 22(1):113-125. PubMed ID: 31822042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics.
    Saotome M; Ikoma T; Hasan P; Maekawa Y
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.
    Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H
    Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of various risk factors on the level of ST2 biomarker in patients with heart failure and diabetes mellitus type 2.
    Rudyk IS; Medentseva OO; Gasanov IC; Babichev DP
    Pol Merkur Lekarski; 2021 Apr; 49(290):95-98. PubMed ID: 33895752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
    Ofstad AP; Atar D; Gullestad L; Langslet G; Johansen OE
    Heart Fail Rev; 2018 May; 23(3):303-323. PubMed ID: 29516230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Liuwei Dihuang decoction on PI3K/Akt signaling pathway in liver of type 2 diabetes mellitus (T2DM) rats with insulin resistance.
    Dai B; Wu Q; Zeng C; Zhang J; Cao L; Xiao Z; Yang M
    J Ethnopharmacol; 2016 Nov; 192():382-389. PubMed ID: 27401286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001-2015).
    Muñoz-Rivas N; Jiménez-García R; Méndez-Bailón M; Hernández-Barrera V; de Miguel-Díez J; Lorenzo-Villalba N; de Miguel-Yanes JM; López-de-Andrés A
    Eur J Intern Med; 2019 Jan; 59():53-59. PubMed ID: 30143395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure.
    Johansson I; Dahlström U; Edner M; Näsman P; Rydén L; Norhammar A
    J Am Coll Cardiol; 2016 Sep; 68(13):1404-1416. PubMed ID: 27659462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.
    Seferović PM; Jhund PS
    Eur Heart J Suppl; 2019 Dec; 21(Suppl M):M20-M24. PubMed ID: 31908611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.